Tirasemtiv in patients with ALS

• Research type

  Research Study

• Full title

  A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)

• IRAS ID

  117268

• Contact name

  Pamela Shaw

• Sponsor organisation

  Cytokinetics Inc

• Eudract number

  2012-004987-23

• Clinicaltrials.gov Identifier

  NCT01709149

• Research summary

  Amyotrophic Lateral Sclerosis, ALS, is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement. Riluzole is the only approved medication for the treatment of ALS, prolonging survival or time to tracheostomy by approximately 2-3 months. CK-2017357 (Tirasemtiv) has been demonstrated to increase the skeletal muscle force in response to lower motor neurone input and also to delay or reduce muscle fatigue during repeated or sustained muscle contraction. Hence Tirasemtiv may be useful in the treatment of patients with ALS.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  13/NW/0026

• Date of REC Opinion

  24 Jan 2013

• REC opinion

  Favourable Opinion